COVID-19 is an emerging, rapidly evolving situation.
Get the latest public health information from CDC: https://www.coronavirus.gov.

Get the latest research information from NIH: https://www.nih.gov/coronavirus.
Working…
ClinicalTrials.gov
ClinicalTrials.gov Menu

Pharmacokinetic Profile of Neupro Patch Administrated at 2 mg, 4 mg, 6 mg and 8 mg/Day Weekly in Patients With Early-stage Parkinson's Disease

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT02728947
Recruitment Status : Completed
First Posted : April 5, 2016
Last Update Posted : December 5, 2016
Sponsor:
Information provided by (Responsible Party):
Luye Pharma Group Ltd.

Brief Summary:
To study the profile of Neupro patch administrated at 2 mg, 4 mg, 6 mg and 8 mg/day weekly in patients with early-stage Parkinson's disease

Condition or disease Intervention/treatment Phase
Parkinson's Disease Drug: ROTIGOTINE Phase 1

Detailed Description:
A single group and open-label study to evaluate pharmacokinetic profile of Neupro patch administrated at 2 mg, 4 mg, 6 mg and 8 mg/day weekly in patients with early-stage Parkinson's disease

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 28 participants
Allocation: Non-Randomized
Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: A Single Group and Open-label Study to Evaluate Pharmacokinetic Profile of Neupro Patch Administrated at 2 mg, 4 mg, 6 mg and 8 mg/Day Weekly in Patients With Early-stage Parkinson's Disease
Study Start Date : May 2016
Actual Primary Completion Date : August 2016
Actual Study Completion Date : September 2016

Resource links provided by the National Library of Medicine

Drug Information available for: Rotigotine

Arm Intervention/treatment
Active Comparator: 2mg
1 week on 2mg/24 hr patch
Drug: ROTIGOTINE
1 week at each dose
Other Name: Neupro

Active Comparator: 4mg
1 week on 4mg/24hr patch
Drug: ROTIGOTINE
1 week at each dose
Other Name: Neupro

Active Comparator: 6mg
1 week on 6mg/24hr patch
Drug: ROTIGOTINE
1 week at each dose
Other Name: Neupro

Active Comparator: 8mg
1 week on 8mg/24hr patch
Drug: ROTIGOTINE
1 week at each dose
Other Name: Neupro




Primary Outcome Measures :
  1. CMax of ROTIGOTINE [ Time Frame: 38 Days ]
    PK parameters Cmax-ss



Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   18 Years to 99 Years   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  1. Patient who is capable of giving informed consent and complying with study procedures
  2. Patient who has Idiopathic Parkinson's Disease defined by the cardinal sign, bradykinesia, plus the presence of at least 1 of the following: resting tremor, rigidity, or impairment of postural reflexes, and without any other known or suspected cause of Parkinsonism
  3. Patient who is Hoehn & Yahr stage less than or equal to 3
  4. Patient who is male or female aged greater than or equal to 18 years at Screening
  5. Patient who has a Mini Mental State Examination (MMSE) score of greater than or equal to 25
  6. Patient who has a Unified Parkinson's Disease Rating Scale (UPDRS) motor score (Part III) of greater than or equal to 10 but less then or equal to 30 at Screening

Exclusion Criteria:

  1. Patient who has atypical Parkinson's syndrome(s) due to drugs (e.g., metoclopramide, flunarizine), metabolic neurogenetic disorders (e.g., Wilson's Disease), encephalitis, cerebrovascular disease, or degenerative disease (e.g., progressive Supranuclear Palsy)
  2. Patient who has a history of pallidotomy, thalamotomy, deep brain stimulation, or fetal tissue transplant
  3. Patient who has dementia, active psychosis or hallucinations, or clinically significant depression
  4. Patient who has a lifetime history of suicide attempt (including an active attempt, interrupted attempt, or aborted attempt), or has suicidal ideation in the past 6 months as indicated by a positive response ("Yes") to either Question 4 or Question 5 of the Columbia-Suicide Severity Rating Scale (C-SSRS) at Screening
  5. Patient who has a history of symptomatic orthostatic hypotension with a decrease of less than or equal to 20 mmHg in systolic blood pressure (SBP) or great than or equal to 10 mmHg in diastolic blood pressure when changing from supine to standing position after having been at supine position for at least 5 minutes within 28 days prior to the Screening Visit, or SBP less than 105 mmHg at study entry, or reports clinical signs of clinically significant orthostatic hypotension within 28 days prior to the Screening Visit.
  6. Patient who is receiving therapy with a dopamine agonist either concurrently or has done so within 28 days prior to the Screening
  7. Patient who is receiving therapy with 1 of the following drugs either concurrently or within 28 days prior to screening: MAO-B inhibitors, DA releasing agents, DA modulating agent, DA antagonists, neuroleptics, or other medications that may interact with DA function.
  8. Patient who is currently receiving central nervous system active therapy (e.g., sedatives, hypnotics, antidepressants, anxiolytics), unless the dose has been stable for at least 28 days prior to Screening Visit and is likely to remain stable for the duration of the study. Patients should not take those medications within 8 hours prior to clinical visits
  9. Patient who has a current diagnosis of epilepsy, has a history of seizures as an adult, has a history of stroke, or has had a transient ischemic attack within 1 year prior to Screening
  10. Patient who has a history of known intolerance/hypersensitivity to non-dopaminegic antiemetics, such as domperidone, ondansetron, tropisetron, and glycopyrrolate
  11. Patient who has any other clinically relevant hepatic, renal and cardiac dysfunction, or other medical condition or laboratory abnormality including abnormal plasma magnesium level, which would in the judgment of the investigator, interfere with the patient's ability to participate in the study
  12. Patient who has a history of significant skin hypersensitivity to adhesive or other transdermal preparations or recent unresolved contact Dermatitis
  13. Patient with C-reactive protein levels of 2x of upper limit of normal range
  14. Female patient who is pregnant or is breastfeeding or is of childbearing potential without adequate contraception.
  15. Patient with a positive finding in drug screening test or alcohol test

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT02728947


Locations
Layout table for location information
United States, California
CNS Network
Long Beach, California, United States, 90806
United States, Florida
MD Clinical
Hallandale Beach, Florida, United States, 33009
United States, Georgia
Atlanta Center for Medical Research
Atlanta, Georgia, United States, 30331
Sponsors and Collaborators
Luye Pharma Group Ltd.
Investigators
Layout table for investigator information
Study Chair: Simon Li, MD Luye Pharma
Layout table for additonal information
Responsible Party: Luye Pharma Group Ltd.
ClinicalTrials.gov Identifier: NCT02728947    
Other Study ID Numbers: LY03003-CT-USA-103
First Posted: April 5, 2016    Key Record Dates
Last Update Posted: December 5, 2016
Last Verified: December 2016
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: No
Keywords provided by Luye Pharma Group Ltd.:
Parkinson's Disease
Additional relevant MeSH terms:
Layout table for MeSH terms
Parkinson Disease
Parkinsonian Disorders
Basal Ganglia Diseases
Brain Diseases
Central Nervous System Diseases
Nervous System Diseases
Movement Disorders
Neurodegenerative Diseases
Rotigotine
Dopamine Agonists
Dopamine Agents
Neurotransmitter Agents
Molecular Mechanisms of Pharmacological Action
Physiological Effects of Drugs